

# IMPAKT CONFERENCE PROGRAMME

---

## Thursday, 8 May 2014

---

13:00/ **Official welcome** **GOLD HALL**  
13:15

13:00 Welcome to the IMPAKT Conference  
*Martine Piccart, Brussels, Belgium*

13:05 Scientific Introduction to the IMPAKT Conference  
*Giuseppe Curigliano, Milan, Italy and  
Alastair M.Thompson, Houston, TX, US*

---

13:15/ **Opening Keynote lecture** **GOLD HALL**

14:00 *Chairs: Mitchell Dowsett, London, UK and  
Martine Piccart, Brussels, Belgium*

13:15 Patient-derived tumour xenografts as models for  
breast cancer drug development  
*Mike T. Lewis, Houston, TX, US*

13:45 Q&A

---

14:00/ **Xenopatients and mouse models to** **GOLD HALL**  
15:30 **predict drug sensitivity and resistance**  
**in breast cancer**

*Chairs: Angelo Di Leo, Prato, Italy and  
Christos Sotiriou, Brussels, Belgium*

14:00 Understanding the determinants of drug sensitivity  
and resistance in mouse models of human HER 2  
positive breast cancer  
*Kent Osborne, Houston, TX, US*

14:20 Modelling of response to treatment in human breast  
cancer xenografts  
*Elisabetta Marangoni, Paris, France*

14:40 Empirical tumourgraft testing and deep sequencing  
data in patient care  
*Charles M. Perou, Chapel Hill, NC, US*

15:00 Clinical perspectives and debate:  
Xenograft models of solid tumours: Problems, pitfalls  
and future directions  
*Pro Speaker: Geoff Lindeman, Parkville, Australia  
Contra Speaker: Angelo Di Leo, Prato, Italy*

15:20 Q&A / General discussion

---

15:30 Coffee break

---

---

**16:00/ Best abstracts session - Oral presentations**

**GOLD HALL**

**17:30** *Chairs: Giuseppe Curigliano, Milan, Italy and Alastair M.Thompson, Houston, TX, US*

**16:00 120** - Molecular subtype of breast cancer metastases significantly influences patient post-relapse survival  
*Nicholas Tobin, Stockholm, Sweden*

**16:10 130** - Evolutionary patterns of microRNA expression through the course of disease and therapy in recurrent breast cancer  
*Maya Dadiani, Ramat Gan, Israel*

**16:20 200** - Analysis of molecular scores for the prediction of distant recurrence according to body mass index and age at baseline  
*Ivana Sestak, London, UK*

**16:30 210** - A novel methylation signature that reflects intratumoral lymphocyte infiltration in breast cancer and predicts for response to anthracycline treatment  
*Jana Jeschke, Brussels, Belgium*

**16:40** Discussant Abstracts 120, 130, 200 and 210  
*Peter Dubsy, Vienna, Austria*

**16:55 590** - Targeting CDK4/6 in Her2 positive breast cancer: Therapeutic effect, markers, and combination strategies  
*Erik Knudsen, Dallas, TX, US*

**17:05 650** - Generation of mouse models for the identification of new driver pathways of drug resistance in human breast cancer (BC)  
*Carmen Criscitiello, Naples, Italy*

**17:15** Discussant Abstracts 590 and 650  
*Nicholas Turner, London, UK*

---

**17:30 Welcome reception and Poster Walk**  
See page 30 for details

**DELVAUX  
FOYER**

# Friday, 09 May 2014

---

08:30/ **Keynote lecture**

**GOLD HALL**

09:15 *Chairs: Alberto Bardelli, Candiolo, Italy and  
Kent Osborne, Houston, TX, US*

08:30 Liquid biopsies to monitor response and resistance to  
targeted therapies  
*Alberto Bardelli, Candiolo, Italy*

09:00 Q&A

---

09:15/ **Liquid biopsies: Genotyping circulating  
10:30 tumour DNA in breast cancer**

**GOLD HALL**

*Chairs: Fabrice André, Villejuif, France and  
Daniel F. Hayes, Ann Arbor, MI, US*

09:15 Circulating exosomes and microRNAs  
*Salvatore Pece, Milan, Italy*

09:35 Circulating tumour cells: Isolation, enrichment and  
clinical value  
*Michail Ignatiadis, Brussels, Belgium*

09:55 Clinical perspectives and debate:  
Liquid biopsies for genotyping and monitoring breast  
cancer: Ready for prime time?  
*Pro Speaker: Daniel F. Hayes, Ann Arbor, MI, US  
Contra Speaker: Mitchell Dowsett, London, UK*

10:15 Q&A / General discussion

---

10:30 Coffee break

---

11:00/ **Ethical and legal barriers to large molecular  
12:15 sequencing projects**

**GOLD HALL**

*Chairs: Lisa A. Carey, Chapel Hill, NC, US and  
Lucy Connolly, Hinxton, UK*

11:00 Overcoming operational challenges of personalised  
cancer therapy  
*Fraser Symmans, Houston, TX, US*

11:15 Consent forms in genomics: Assessing the privacy  
risks of data sharing  
*Katherine Nathanson, Philadelphia, PA, US*

11:30 Ethical, legal and social implications of the use of  
whole genome methods in medical research  
*Harriet Teare, Oxford, UK*

11:45 Visualising the true spectrum of cancer by molecular  
sequencing: Will we get convergence from divergence?  
*Lucy Connolly, Hinxton, UK*

12:00 Q&A / General discussion

---

12:15/	INDUSTRY SATELLITE SYMPOSIUM	SILVER HALL
13:15	<b>Exploring biomarkers of efficacy and resistance in estrogen receptor–positive and HER2-positive advanced breast cancer: Let’s make it personal</b> See page 39 for details	
13:15	Lunch	
13:45/	INDUSTRY SATELLITE SYMPOSIUM	GOLD HALL
15:15	<b>From biology to oncology: Targeting ER+/HER2– breast cancer</b> See page 39 for details	
15:15	Coffee break	
15:30/	<b>Keynote Lecture</b>	GOLD HALL
16:15	<i>Chairs: Fabrice André, Villejuif, France and Karen Willard-Gallo, Brussels, Belgium</i>	
15:30	Defining critical hurdles in cancer immunotherapies <i>George Coukos, Lausanne, Switzerland</i>	
16:00	Clinical implications of immune modulation in breast cancer <i>Fabrice André, Villejuif, France</i>	
16:15/	<b>Biomathematics in the development of personalised medicine in oncology</b>	GOLD HALL
17:45	<i>Chairs: Mark Chaplain, Dundee, UK and Alastair M.Thompson, Houston, TX, US</i>	
16:15	Calibrating breast cancer simulations with patient pathology: Progress and future steps <i>Paul Macklin, Los Angeles, LA, US</i>	
16:35	Mathematical modelling of cancer from cell to tissue level <i>Mark Chaplain, Dundee, UK</i>	
16:55	High dimensional biomarkers as treatment modifiers in randomised clinical trials <i>Stefan Michiels, Villejuif, France</i>	
17:15	Clinical perspectives <i>Alastair M.Thompson, Houston, TX, US</i>	
17:30	Q&A / General discussion	
17:45/	<b>How can international collaboration benefit young researchers?</b>	GOLD HALL
18:30	<i>Panellists: Fabrice André, Villejuif, France; Giuseppe Curigliano, Milan, Italy; Evandro De Azambuja, Brussels, Belgium; Carsten Denkert, Berlin, Germany; Phuong Dinh, Sydney, Australia; Peter Dubsy, Vienna, Austria; Sibylle Loibl, Neu-Isenburg, Germany; Alastair M. Thompson, Houston, TX, US</i>  Early-career breast cancer specialists will share their own experience with international collaboration: What have been the benefits, but also the challenges of working on international, collaborative research efforts? How did they get involved with such projects? Panellists will be available to answer questions.	

# Saturday, 10 May 2014

---

08:30/10:00 **Debate: Should prognostic genomic tests be “routinely” used in clinical practice? Updates and news since the 2012 edition** **GOLD HALL**

*Chairs: Christos Sotiriou, Brussels, Belgium and Fraser Symmans, Houston, TX, US*

08:30 Updates and news since the 2012 edition  
*Fraser Symmans, Houston, TX, US*

08:45 Utility of prognostic genomic tests in breast cancer practice: IMPAKT international expert opinion for utility of prognostic genomic tests in breast cancer practice  
*Panellists: Hatem A. Azim Jr., Brussels, Belgium; Fabrice André, Villejuif, France; Giuseppe Curigliano, Milan, Italy; Angelo Di Leo, Prato, Italy; Christine Desmedt, Brussels, Belgium; Mitchell Dowsett, London, UK; Peter Dubsy, Vienna, Austria; Daniel F. Hayes, Ann Arbor, MI, US; Stefan Michiels, Villejuif, France; Kent Osborne, Houston, TX, US; Charles M. Perou, Chapel Hill, NC, US; Martine Piccart, Brussels, Belgium; Jorge Reis-Filho, New York, NY, US; Christos Sotiriou, Brussels, Belgium; Charles Swanton, London, UK; Alastair M. Thompson, Houston, TX, US; Nicholas Turner, London, UK; Andrew Tutt, London, UK and Giuseppe Viale, Milan, Italy*

---

10:00 Coffee break

---

10:30/10:45 **Susan G. Komen for the Cure® award session** **GOLD HALL**

---

10:45/12:35 **New drugs and trials on the horizon** **GOLD HALL**

*Chairs: Mitchell Dowsett, London, UK and Peter Dubsy, Vienna, Austria*

10:45 Personalised medicine in breast cancer: Where have we come from and where are we going?  
*Fabrice André, Villejuif, France*

11:05 The AURORA initiative for advanced breast cancer  
*Martine Piccart, Brussels, Belgium*

11:25 Whole-genome sequencing and cancer therapy: What is too much?  
*Jorge Reis-Filho, New York, NY, US*

11:45 “Genome-Forward” trials  
*Lisa A. Carey, Chapel Hill, NC, US*

12:05 Targeting the CDK4/6 pathways  
*Luca Malorni, Prato, Italy*

12:25 Q&A / General discussion

---

12:35/12:45 **Closing remarks and introduction of the IMPAKT 2015 Chairs** **GOLD HALL**

*Giuseppe Curigliano, Milan, Italy and Alastair M. Thompson, Houston, TX, US*